With more M&A, product development and restructuring on the horizon, med tech CEOs have their work cut out for them in the coming year. But for now, here's the breakdown of what they took home in 2013.
Johnson & Johnson's Janssen Pharmaceuticals unit has notified the FDA that it has made a business decision to discontinue the production of its antibiotic Levaquin.
New drug approvals may have dropped from 2012's high of 43 to 35 last year. But that doesn't mean 2013's crop lacks superstars.
When Johnson & Johnson Innovation debuted about a year ago, R&D chief Paul Stoffels promised to build an interconnected, global operation that would sink some deep roots into the world's busiest biotech hubs. On Thursday, the group showed off just how far it had come in a short time.
With all hands on deck at Vertex focused on the development of a crucial combo drug for cystic fibrosis, the Boston-based biotech has outlicensed an influenza drug to J&J in exchange for a $30 million upfront.
Johnson & Johnson committed to financing early stage companies through its Innovation Centers scattered around the globe that launched more than a year ago. Now it's unveiling a dozen alliances that it has made lately with life science companies and research institutions.
Johnson & Johnson Innovation has announced a slate of a dozen new deals, ranging from fresh research collaborations to new investments in a range of upstart drug and device developers--all aimed at putting the multinational pharma giant on the cutting edge of new product development.
It's no secret that consumers respond to everyday people--just like them--in advertisements. So when Johnson & Johnson wanted to reach out to the Hispanic community, that's just who it set out to find.
I'm not a doctor, but I play one on TV. That approach has put pharma in the doghouse before. But now, here's a new question. What about, "I'm not a patient, but I play one in a promo campaign for doctors"?
Johnson & Johnson has signed a deal with ViiV Healthcare, the HIV-focused venture majority-owned by GlaxoSmithKline, to spin their two antivirals into a single tablet.